Irl Hirsch

2 weeks ago | ajmc.com | David G. Marrero |Christopher Parkin |Grazia Aleppo |Irl Hirsch |Janet B. McGill |Rodolfo J. Galindo | +4 more

PublicationArticleApril 7, 2025The American Journal of Managed CareApril 2025Volume31 Issue 4Author(s):,This article reviews underlying barriers to health care access and discusses how a value-based diabetes care model could improve patient outcomes and reduce long-term costs.

1 month ago | healio.com | Michael Monostra |Richard Smith |Irl Hirsch

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

1 month ago | healio.com | Emma Bascom |Michael Monostra |Bob Herpen |Irl Hirsch

On Feb. 14, the FDA approved the first biosimilar insulin aspart by the name of Merilog. The hope is that this rapid-acting analog to be used for mealtime insulin with multiple injections or insulin pump therapy would further increase access to insulin treatment options with lower costs. While many applaud this addition to the U.S. formulary, the situation is more complex than it was a few years ago. While expensive, retail prices today are lower than in the past.

Oct 15, 2024 | healio.com | Erik Swain |Richard Smith |Irl Hirsch

Irl B. Hirsch, MD, MACP Let's recall that insulin pricing today is better for Medicare recipients ($35 per month) but this missed the mark for commercial payors in 2022 by 3 U.S. Senate votes. Fifty-seven senators, including 7 Republicans, voted for the $35 per month for all, but since 60 votes were required, the bill did not pass.

Aug 2, 2023 | reachmd.com | Irl Hirsch

Since the insulin pump started widespread use in the early 1980s, it’s become the option of choice for type 1 diabetes patients to manage their glucose levels in a way that doesn’t require testing their blood sugar and injecting insulin multiple times daily. But now, a first-of-its kind study is looking at the issue of patients “running out of real estate” due to pump sites becoming fibrotic, irritated and less effective at delivering insulin.